NICE launches scientific advice tie-up with Canadian agencyThe UK’s cost-effectiveness regulator NICE and the its counterpart in Canada have launched a new collaboration to offer Share XNICE launches scientific advice tie-up with Canadian agencyhttps://pharmaphorum.com/news/nice-launches-scientific-advice-tie-up-with-canadian-agency/
Novartis and Lilly CEOs back Trump plans to cut drug pricesCEOs from Novartis and Eli Lilly have backed US government proposals to cut out “middlemen” in the health Share XNovartis and Lilly CEOs back Trump plans to cut drug priceshttps://pharmaphorum.com/news/novartis-and-lilly-ceos-back-trump-plans-to-cut-drug-prices/
Vertex calls for changes to NICE as CF drug profits soarVertex has revealed financial figures that are likely to go down well with investors, but not patients in Share XVertex calls for changes to NICE as CF drug profits soarhttps://pharmaphorum.com/news/vertex-calls-for-changes-to-nice-as-cf-drug-profits-soar/
Campaigners urge NHS to ignore patents on Vertex’s CF drugThe fight to get Vertex’s cystic fibrosis drug Orkambi available on England’s NHS continues, after pressure groups called Share XCampaigners urge NHS to ignore patents on Vertex’s CF drughttps://pharmaphorum.com/news/campaigners-urge-nhs-to-ignore-patents-on-vertexs-cf-drug/
NICE aims to improve communications with UK life sciencesNICE has announced a collaboration with an organisation representing UK life sciences, to improve communications between the cost-effectiveness Share XNICE aims to improve communications with UK life scienceshttps://pharmaphorum.com/news/nice-aims-to-improve-communications-with-uk-life-sciences/
Cystic fibrosis patients lobby Vertex to drop drug pricesHealthcare professionals and patient groups have written to Vertex’s CEO Jeffrey Leiden in a bid to resolve a Share XCystic fibrosis patients lobby Vertex to drop drug priceshttps://pharmaphorum.com/news/cystic-fibrosis-patients-lobby-vertex-to-drop-drug-prices/
Market access roundup: The US fights back against price hikesDon’t expect the US government’s war on drug pricing to go away any time soon – for once Share XMarket access roundup: The US fights back against price hikeshttps://pharmaphorum.com/views-analysis-market-access/market-access-roundup-the-us-fights-back-against-price-hikes/
NICE assessments could reform in new superbug planThe UK government has published a new five year plan aimed at tackling antimicrobial resistance (AMR), including a Share XNICE assessments could reform in new superbug planhttps://pharmaphorum.com/news/nice-assessments-could-reform-in-new-plan-to-tackle-amr/
Pharma stocks fall after new drug price probe in USUS politicians from the resurgent Democratic party have launched a probe into “unsustainable” drug price rises, prompting their Share XPharma stocks fall after new drug price probe in UShttps://pharmaphorum.com/news/pharma-stocks-fall-after-new-drug-price-probe-in-us/
